Low-grade malignant lymphoma - present therapy and future directions;NIEDRIGMALIGNE NON-HODGKIN-LYMPHOME - AKTUELLER STAND UND PERSPEKTIVEN DER THERAPIE

Therapeutische Umschau

Volumn 53, Issue 2, 1996, Pages 123-132

  Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; VINCRISTINE;

HUMAN; LYMPHOMA; REVIEW;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; INTERFERON-ALPHA; LYMPHOMA, LOW-GRADE; PROGNOSIS; RADIOTHERAPY;

EID: 0029939270     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Gerard-Marchant R. et al.: Classification of Non-Hodgkin's lympomas. Lancet II, 406-408, 1974.
2. Starnsfeld A. G. et al.: Updated Kiel classification for lymphomas. Lancet I, 292-293, 603, 1988.
3. Lennert K., Feller A. C.: Histopathology of Non-Hodgkin's lymphomas (based on the updated Kiel classification). Springer, Berlin, Heidelberg, New York, 1992.
4. Harris N. L., Jaffe E. S., Stein H. et al.: A proposal for an international consensus on the classification of lymphoid neoplasms. Blood (in press).
5. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of Non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49, 2112-2135, 1982.
6. Engelhard M. et al.: Klinisch relevante Prognosefaktoren maligner Lymphome. Internist 34, 127-131, 1993.
7. Brittinger G. et al.: Strategien der Behandlung von Non-Hodgkin-Lymphomen. Internist 27, 485-497, 1986.
8. Homing S. J. et al.: The natural history of initially untreated low-grade Non-Hodgkin's lymphomas. N. Engl. J. Med. 37, 1471-1475, 1984.
9. Gallagher G. J. et al.: Follicular lymphoma: prognostic factors for response and survival. J. Clin. OnCol. 4, 1470-1480, 1986.
10. Vandenberghe E.: Mantle cell lymphoma. Blood Cell Reviews 8, 79-87, 1994.
11. Tsujimoto Y. et al.: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1037-1090, 1985.
12. Korsmeyer S. J.: Bcl-2 initiates a new category of oncogenes regulators of cell death. Blood 80, 879-886, 1992.
13. Tesch H. et al.: Zell- und Molekularbiologie von malignen Lymphomcn. Internist 34, 89-96, 1993.
14. Yunis et al.: Multiple recurrent genomic defects in follicular lymphoma - a possible model for cancer. N. Engl. J. Med. 316, 79-84, 1987.
15. Gauwerky C. E. et al.: Evolution oi B-cell malignancy: pre-B-cell leukemia resulting from MCY activation in a B-cell neoplasm with rearranged bcl-2 gene. Proc. Natl. Acad. Sci. 85, 8548-8552, 1988.
16. McDonnell T. J. et al.: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the ((14;18). Nature 543, 254-256, 1991.
17. Weisenburger D. D. et al.: Intermediate lymphocytic lymphoma: immunophenocytic and cytogenetic findings. Blood 69, 1617-1621, 1987.
18. Rosenberg C. L. et al.: PRADI, a candidate bcl-1 oncogene: mapping and expressing in controcytic lymphoma. Proc. Natl. Acad. Sci. 88, 9638-9642, 1991.
19. Swerdlow S. H. et al.: Centrocytic lymphoma: a distinct clinicopathologic, immunophenotypic, and genotypic entity. Pathol. Ann. 28 (Part 2). 171-197, 1991.
20. Palinero I. et al.: Cyclins D1 and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene 8, 1049-1054, 1993.
21. Arinalige J. O.: Treatment of Non-Hodgkin's lymphoma. N. Engl. J. Med. 320, 1023-1030, 1992.
22. Weisenburger D. D.: Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic. Ann. Oncol. 5 (Suppl. 1), 19-24, 1994.
23. Brittinger G. et al.: Klinische und prognostische Relevanz der Kiel-Klassifikation der Non-Hodgkin-Lymphome. Onkologie 9, 118-125, 1986.
24. Fuller L. M. et al.: The natural history of Non-Hodgkin's lymphomata stages I and II. Br. J. Cancer 31 (Suppl. 2), 270-285, 1975.
25. Gospodarowicz M. K. et al.: Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int. J. Radiat. Oncol. Phys. 10, 489-497, 1984.
26. Paryani S. B. et al.: Analysis of Non-Hodgkin's lymphomas with nodular and favorable histologies, stage I and II. Cancer 52, 2300-2307, 1983.
27. Sutcliffe T. S., Gospodarowicz M. K., Bush R. S. et al.: Role of radiation therapy in localized Non-Hodgkin's lymphoma. Radioth. Oncol. 4, 221-223, 1985.
28. McLaughlin P. et al.: Stage I-II follicular lymphoma. Cancer 58, 1596-1602, 1986.
29. Gomez G. A., Barlos M., Krishnamsetty R. M. et al.: Treatment of early stage I and II nodular poorly differentiated lymphocytic lymphoma. Am. J. Clin. Oncol. 9, 40-47, 1986.
30. Lawrenz T. S., Urba W. J., Steinberg S. M. et al.: Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int. J. Rad. Oncol. Biol. Phys. 14, 417-424, 1988.
31. Richards M. A. et al.: Management of localized Non-Hodgkin's lymphoma: the experience at St. Bartholomew's Hospital 1972-1985. Hematol. Oncol. 7, 1-18, 1989.
32. Epelbaum R., Kuten A., Coachman N. M. et al.: Stage I-II low grade Non-Hodgkin's lymphoma: prognostic factors and treatment results. Strahlenth. Onkol. 168 (2), 66-72, 1992.
33. Sack H. et al.: Non-Hodtgkin Lymphomas (NHL) - early stages interim results of a multicentre trial. Cancer Res. Clin. Oncol. 118 (Suppl.) R 115, 1992.
34. Jacobs J. P., Murray K. J., Schultz J. F. et al.: Central lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J. Clin. Oncol. 11, 233-238, 1993.
35. Yahalom J., Varsos G., Fuks Z. et al.: Adjuvant Cyclophosphamide, Doxorubicin, Vincristine and Prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate grade Non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71, 2342-2350, 1993.
36. Cox J. D. et al.: Stage III nodular lympho-reticular tumors (Non-Hodgkin's lymphoma):results of central lymphatic irradiation. Cancer 47, 3347-3352, 1981.
37. Paryani S. B. et al.: The role of radiation therapy in the management of stage III follicular lymphomas. J. Clin. Oncol. 2, 841-848, 1984.
38. McLaughlin P. et al.: Stage I-II low-grade lymphomas: a prospective trial of combination chemotherapy and radiotherapy. Ann. Oncol. 2 (Suppl. 2), 137-140, 1991.
39. Carde P. et al.: Combination radiotherapy - chemotherapy for early stages Non-Hodgkin's lymphoma: the 1975-1980 EORTC controlled lymphoma trial. Radiother. Oncol. 2, 301-312, 1984.
40. Nissen N. I. et al.: A randomized study of radiotherapy versus radiotherapy plus chemotherpy in stage I-II Non-Hodgkin's lymphomas. Cancer 52, 1-7, 1983.
41. Anderson J. R., Vose J. M., Bierman P. J. et al.: Clinical features and prognosis of follicular large-cell lymphoma: a report from Nebraska Lymphoma study group. J. Clin. Oncol. 11, 218-224, 1993.
42. Young R. C. et al.: The treatment of indolent lymphomas: watchful waiting vs. aggressive combined modality treatment. Semin. Hematol. 25 (Suppl. 2), 11-16, 1988.
43. Longo D.: What's the deal with follicular lymphomas? J. Clin. Oncol. 2, 202-208, 1993.
44. Portlock C.S., Fischer D. S., Cadman E. et al.: High-dose pulse Chlorambucil in advanced, low-grade Non-Hodgkin's lymphoma. Cancer Treat. Rep. 71, 1029-1031, 1987.
45. Ezdinli E. Z. et al.: Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J. Clin. Oncol. 3, 769-775, 1985.
46. Kirnby E., Björkorholm M., Gahrton G. et al.: Chlorambucil/prednisone vs. CHOP in symptomatic low-grade Non-Hodgkin's lymphomas: A randomised trial from the Lymphoma Group of Central Sweden. Ann. Oncol. 5 (Suppl. 2), 67-71, 1994.
47. Nissen N. I. et al.: High activity of daily-schedule mitoxantrone in newly diagnosed low-grade Non-Hodgkin's lymphomas: a 5-year follow-up. Sem. Oncol. 6 (Suppl. 10), 10-13, 1990.
48. Bagley C. M. et al.: Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vinicristinc and prednisone. Ann. Intern. Med. 76, 227-234, 1972.
49. Steward W. P. et al.: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic Lype Non-Hodgkin's lymphoma. Cancer 61, 441-447, 1988.
50. Unterhalt M., Koch P., Pfreundschuh M. et al.: Prednimustine, Mitoxantrone [PmM) versus Cyclophosphamide, Vincristine, Prednisone (COP) for the treatment of advanced low grade Non-Hodgkin lymphoma. Blood 84 (Suppl. 1), 168a, 1994.
51. Unterhalt M., Herrmann R., Tiemann M. et al.: Prednimustine, Mitoxantrone (PmM) versus Cyclophosphamide, Vincristine, Prednisone (COP) for the treatment of advanced low grade Non Hodgkin lymphoma. Leukemia (in press).
52. Hagenbeek A. et al.: Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant Non-Hodgkin's lymphoma. Results from a prospective, randomised phase III clinical trial in 331 patients. Blood 80 (Suppl. 1), 74a, 1992.
53. Jones S. E. et al.: Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. Cancer 51, 1083-1090, 1983.
54. Dana B. W. et al.: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J. Clin. Oncol. 11, 644-651, 1993.
55. Peterson B. A. et al.: Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML). Proc. Am. Soc. Clin. Oncol. 9, 259, 1990.
56. Romaguera J. E., McLaughlin P., North L. et al.: Multivariate analysis of prognostic factors stage IV follicular low-grade lymphoma: a risk model. J. Clin. Oncol. 9, 762-769, 1991.
57. Velasquez W. S., McLaughlin P., Fuller L. M. et al.: Intermediate-grade lymphomas treated with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bleomycine alternated with Cyclophosphamide, Methotrexate, Etoposide, Dexamethasone. Cancer 73, 2408-2416, 1994.
58. Anderson K. C. et al.: Combination chemotherapy for advanced Non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Cancer Treat. Rep. 68, 1343-1350, 1984.
59. Licht J. D. et al.: Treatment of low-grade and intermediate-grade lymphoma with intensive combination chemotherapy results in long-term disease-free survival. Cancer 66, 632-639, 1990.
60. Canellos G. P., Sharin A. T., Klatt M. M. et al.: The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Sem. Hematol. 24, 2-7, 1987.
61. Klimo P., Connors J. M.: Updated clinical experience with MACOP-B. Sem. Hematol. 24 (Suppl. 1), 26-34, 1987.
62. Unterhalt M. et al.: Significant prolongation of disease free survival in advanced low grade non Hodgkin lymphomas (NHL) by interferon alpha maintenance. Blood 86 (Suppl. 1), 439a, 1995.
63. Hiddemann W. et al.: New aspects in the treatment of advanced low-grade Non-Hodgkin's lymphomas: prednimustine/mitoxantrone [PmM) vs. cyclophosphamide/vincristine/prednisone (COP) followed by interferon-α vs. observation only - a preliminary update of the German Low Grade Lymphoma Study Group. Sem. Oncol. 1994 (in press).
64. Chisesi T. et al.: Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade Non-Hodgkin's lymphoma: an interim report of a randomized study. J. Eur. J. Cancer. 27 (Suppl. 4), 31-33, 1991.
65. Price C. G. A. et al.: Interferon a2b in the treatment of follicular lymphoma: preliminary results of a trial in progress. Ann. Oncol. 2 (Suppl. 2). 141-145, 1991.
66. Peterson B. A. et al.: Cyclophosphamide versus cyclophosphamide plus Interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc. Am. Soc. Clin. Oncol. 12, 366, 1993.
67. Hochster H. S. et al.: Activity of fludarabine in previously treated Non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group Study. J. Clin. Oncol. 10, 28-32, 1992.
68. Redmuin J. R. et al.: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J. Clin. Oncol. 10, 790-794, 1992.
69. Pigaditou A. et al.: Fludarabine in low-grade lymphomas. Sem. Oncol. 1994 (in press).
70. Hiddemann W. et al.: Fludarabine single agent therapy for relapsed low grade Non-Hodgkin's lymphomas: a phase II study of the German Low Grade Non-Hodgkin's Lymphoma Study Group. Sem. Oncol. 1994 (in press).
71. Zinzani P. L., Lauria F., Rondelli D. et al.: Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade Non-Hodgkin's lymphoma. Ann. Oncol. 4, 575-578, 1993.
72. Dumontet C., Bastion Y., Bazin M. et al.: Fludarabine therapy in low-grade non Hodgkin's lymphoma (LG-NHL): results of the Lyon-Sud experience. Proc. 5th Int. Conf. Malignant Lymphoma, Lugano, 1993 (abstr.).
73. Bosly A., Ferrant A., Delannoy A. et al.: 2-Chorodeoxyadenosine therapy in Non-Hodgkin's lymphoma. Blood 82 (Suppl. 1), 560a, 1993.
74. Hoffman M., Tallman M. S., Hakimian D. et al.: 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent Non-Hodgkin's lymphoma. J. Clin. Oncol. 12, 788-792, 1994.
75. Kay A. C. et al.: 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 10, 371-377, 1992.
76. Betticher D. C. et al.: High incidence of infections after 2-chlorodeoxyadenosine (2-CDA)-therapy in patients with various heamotalogical malignancies. Ann. Oncol. 5, 57-64, 1994.
77. Schauten H. C. et al.: Autologous bone marrow transplantation in follicular Non-Hodgkin's lymphoma before and after histologic transformation. Blood 74, 2579-2584, 1989.
78. Freedman A. S. et al.: Autologous bone marrow transplantation in B-cell Non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J. Clin. Oncol. 8, 784-791, 1990.
79. Vose J. M. et al.: Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell Non-Hodgkin's lymphomas. Blood 76, 424-431, 1990.
80. Freedman A. et al.: Autologous bone marrow transplantation in advanced low grade B-cell Non-Hodgkin's lymphoma in first remission. Blood 82 (Suppl. 1), 332a, 1993.
81. O'Donnell M. R. et al.: High dose therapy (HDT) and autologous G-CSF-primed peripheral blood stem cell transplantation (PBSCT) for follicular low grade lymphoma (FLGL). Blood 82 (Suppl. 1), 145a, 1993.
82. Vose J. M. et al.: Mantle cell lymphoma (MCL) has a poorer prognosis than follicular Non-Hodgkin's lymphoma (F-NHL); however, high-dose therapy (HDC) and autologous stem cell transplantation (ASCT) may overcome treatment resistance in MCL. Blood 82 (Suppl. 1), 135a, 1993.
83. Pettengell R. et al.: Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for Non-Hodgkin's Lymphoma. Blood 82, 2239-2248, 1993.
84. Rohatiner A. Z. S. et al.: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J. Clin. Oncol. 12, 1177-1184, 1994.
85. Morel P., Laporte J. P., Noel M. P. et al.: Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 9, 576-582, 1995.
86. Gribben J. G. et al.: Bone marrows of Non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80, 1083-1089, 1992.
87. Rohatiner A. Z. S., Freedman A., Nadler L., Lim J., Lister T. A.: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma, Ann. Oncol. 5 (Suppl. 2), 143-146, 1994.
88. Schauten H. C., Colombat Ph., Verdonck L. F. et al.: Autologous bone marrow transplantation for low-grade Non-Hodgkin's lymphoma: The European Bone Marrow Transplant Group experience. Ann. Oncol. 5 (Suppl. 2), 147-149, 1994.
89. Haas R., Möhle R., Frühauf S. et al.: Autografting with Filgastrim (R-metHUG-CSF)-mobilized peripheral blood stem cells (PBSC) in malignant lymphoma-predictive factors for mobilization efficiency. Blood 82 (Suppl. 1), 648a, 1993.
90. Colombat Ph., Donadio D., Fouillard L. et al.: Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplantation 15, 157-162, 1994.
91. Stewart D. A., Vose J. M., Weisenburger D. D. et al.: The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann. Oncol. 6, 263-266, 1995.